Navigation Links
ProteoTech Receives Funding From The Michael J. Fox Foundation for Parkinson's Disease Research to Develop Tools for Imaging Alpha-Synuclein Aggregation in Living Parkinson's Brain
Date:3/2/2009

KIRKLAND, Wash., Feb 26 /PRNewswire/ -- ProteoTech Inc. announced today that it has been awarded a grant from The Michael J. Fox Foundation for Parkinson's Disease Research. In collaboration with Avid Radiopharmaceuticals Inc. (Philadelphia, PA), ProteoTech scientists will utilize ProteoTech's small molecule platform drug technology to develop new imaging agents that will allow doctors to use PET imaging to identify and determine the extent of alpha-synuclein accumulation in the living human brain. Alpha-synuclein is a major protein identified in Lewy bodies in the Parkinson's disease brain, and its accumulation in brain is believed to be important in the motor dysfunction observed in Parkinson's patients. The one-and-a-half year project entitled "18-F-labeled Alpha-Synuclein Ligands for PET Imaging of Lewy Bodies" will be led by Dr. Alan Snow, Chairman, President & Chief Scientific Officer of ProteoTech, and Dr. Franz Hefti, Chief Scientific Officer of Avid Radiopharmaceuticals Inc.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090226/SF76109LOGO)

ProteoTech is currently in its 4th year of a LEAPS award funded by The Michael J. Fox Foundation for Parkinson's Disease Research to develop a new small molecule targeting alpha-synuclein in Parkinson's brain. ProteoTech's Synuclere(TM) has been demonstrated to inhibit alpha-synuclein aggregation in the brains of genetically engineered mice that develop motor dysfunction, when alpha-synuclein deposits aggregate and accumulate in brain. The LEAPS award consortium led by Dr. Alan Snow of ProteoTech includes research teams from University of California-San Diego, Boston University, Boston College and Medchem Source Inc.

About ProteoTech: ProteoTech is a private drug development Company founded in 1996 that is a world-leader in therapeutics targeting amyloid diseases. With over 175 patents in its intellectual property estate, ProteoTech is in human clinical trials for its orally active small molecule drug Exebryl-1 for the treatment of mild-to-moderate Alzheimer's disease. The Company is in late-stage pre-clinical development with Synuclere(TM) for the treatment of Parkinson's disease, and Systebryl(TM) for the treatment of Systemic Amyloidosis. ProteoTech is also in late stage pre-clinical development for a novel small peptide called PeptiClere(TM) as a nasal spray for the treatment of Alzheimer's disease. Lastly, ProteoTech is developing a novel small molecule compound for the treatment of amyloidosis associated with type 2 diabetes. For further information, please visit the Company's website at www.proteotech.com or contact us at info@proteotech.com


'/>"/>
SOURCE ProteoTech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. ProteoTech to Present at Rodman & Renshaws 10th Annual Healthcare Conference
2. Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store
3. DaVita Receives Civil Complaint
4. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
5. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
6. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
7. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
8. UT Southwesterns obesity research receives $22 million NIH Roadmap grant
9. Temple Emergency Medicine receives $1.8M to find best MRSA treatment
10. Prime Therapeutics Receives TIPPS Certification
11. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... 13, 2017 , ... Coveros, a leader in agile coaching ... contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile ... of Agile methodologies in a consistent and high value manner across CMS programs. ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... “America On ... Christian identity. “America On The Brink” is the creation of published author, William ... several great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
(Date:10/12/2017)... San Francisco, CA (PRWEB) , ... October 12, ... ... and Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus ... sleep apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults ... tested to meet the highest standard. , These products are also: Gluten ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... The American ... Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium ... 8. , In honor of Morris F. Collen, a pioneer in the field of ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... Texas , Oct. 11, 2017  Caris Life ... focused on fulfilling the promise of precision medicine, today ... has joined Caris, Precision Oncology Alliance™ (POA) as its ... cancer centers, the St. Jude Crosson Cancer Institute will ... advance the use of tumor profiling, making cancer treatment ...
(Date:10/11/2017)... CHICAGO , Oct. 11, 2017  Hill-Rom Holdings, ... its Aspen Surgical facility in Las Piedras, ... surgical scalpels and blades. ... confirmed that the facility sustained minor structural damage, temporary ... Hurricane Maria. Repairs have been completed, manufacturing operations have ...
(Date:10/10/2017)...   West Pharmaceutical Services, Inc. (NYSE: WST), ... administration, today shared the results of a study highlighting ... intradermal administration of polio vaccines. The study results were ... 2017 by Dr. Ondrej Mach , Clinical Trials ... (WHO), and recently published in the journal Vaccine. ...
Breaking Medicine Technology: